Opendata, web and dolomites


GlucoBeam: A portable device for pain-free glucose self-monitoring in diabetic patients

Total Cost €


EC-Contrib. €






 GlucoBeam project word cloud

Explore the words cloud of the GlucoBeam project. It provides you a very rough idea of what is the project "GlucoBeam" about.

extract    innovation    post    device    medium    period    compliance    leverage    requiring    minimizing    electrochemical    intake    balancing    minimum    digit    382    market    errors    costly    concentration    society    prick    secure    position    glucobeam    faced    individual    empowering    invasive    ing    cornerstone    times    refined    proprietary    desired    painful    lancet    successful    patients    carefully    diabetic    spectroscopy    savings    conventional    uncomfortable    strategy    substances    repeating    raman    mellitus    risk    pain    collect    million    world    droplet    quality    added    tissue    critical    self    treatment    diabetes    optical    diet    billion    blood    detecting    day    double    healthcare    insulin    dm    people    turnover    population    thereby    monitoring    commercialization    patient    smbg    significantly    avoiding    modern    aggregated    levels    life    approx    right    foothold    onto    sources    finger    disposable    leads    acute    strip    rsp    glucose    relies    signals    253    exercise    scanning    poor    cured    therapy    30s    ultimately    health    complications    severe   

Project "GlucoBeam" data sheet

The following table provides information about the project.


Organization address
city: ODENSE S
postcode: 5260
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-02-01   to  2016-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RSP SYSTEMS A/S DK (ODENSE S) coordinator 50˙000.00


 Project objective

Diabetes mellitus (DM) is one of the largest health challenges currently faced by modern society, affecting 382 million people in the world. DM cannot be cured, but via well-controlled therapy, a high quality of life with diabetes can be obtained, with a minimum of short- and long-term complications. The key to a successful diabetes therapy is a well-controlled blood glucose level, which is obtained by carefully balancing insulin intake, diet, and exercise and with Self-Monitoring of Blood Glucose (SMBG) as a cornerstone. Conventional SMBG is an invasive test requiring the patient to prick his/her finger with a lancet to extract a blood droplet onto a disposable strip for electrochemical analysis of the glucose concentration. Repeating this uncomfortable and painful task 4-8 times per day leads to severe loss in life quality, often resulting in poor compliance leading to costly complications.

RSP’s proprietary non-invasive SMBG technology relies on the capabilities of Raman spectroscopy for directly detecting individual substances, refined by a unique critical depth optical scanning to collect glucose signals from the right tissue depth range, thus avoiding sources of errors during the measurement. Our GlucoBeam device will enable DM patients to test their glucose levels in around 30s and as often as desired – at no added cost or pain – thereby empowering them to better manage their treatment and minimizing the risk for acute complications.

GlucoBeam’s successful commercialization will position RSP to secure an aggregated turnover of approx. €253 million over the 5 years post-project period. Furthermore, it has the potential to reach double digit billion savings for EU’s healthcare systems and will ultimately lead to significantly improved life quality for the large population of diabetic patients. Moreover, GlucoBeam’s commercialization will allow RSP to set a market foothold in order to leverage its medium term innovation strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLUCOBEAM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLUCOBEAM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More